Crossject released its H1 17 results. Revenues reached €1,635k (vs €1,600k), operating result €-4,256k (vs €-2,779k), and the net result €-3,360k (vs €-2,831k). Net cash at the end of H1 17 was €6,096k vs €2,634k at the end of FY16, including the €4,985k capital increase carried out in March. The company also announced it will engage in the development of a new product (Zeneo Terbutaline) in the field of acute asthma. Lastly, the group indicated th
25 Sep 2017
H1 17: a new NTE in the pipeline...and further delays
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
H1 17: a new NTE in the pipeline...and further delays
Crossject SA (ALCJ:PAR) | 0 0 (-3.4%) | Mkt Cap: 38.7m
- Published:
25 Sep 2017 -
Author:
Fabrice Farigoule -
Pages:
3
Crossject released its H1 17 results. Revenues reached €1,635k (vs €1,600k), operating result €-4,256k (vs €-2,779k), and the net result €-3,360k (vs €-2,831k). Net cash at the end of H1 17 was €6,096k vs €2,634k at the end of FY16, including the €4,985k capital increase carried out in March. The company also announced it will engage in the development of a new product (Zeneo Terbutaline) in the field of acute asthma. Lastly, the group indicated th